Published in J Urol on January 01, 2003
Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05
Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol (2005) 1.34
Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines. Int J Colorectal Dis (2007) 0.90
Targeting Hsp90 in urothelial carcinoma. Oncotarget (2015) 0.87
Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth. Br J Cancer (2004) 0.86
Time and dose dependence of pluronic bioactivity in hyperthermia-induced tumor cell death. Exp Biol Med (Maywood) (2008) 0.85
Downregulated expression of HSP27 in human low-grade glioma tissues discovered by a quantitative proteomic analysis. Proteome Sci (2010) 0.81
Differential gene expression in the testes of different murine strains under normal and hyperthermic conditions. J Androl (2008) 0.80
Retracted Nuclear Ago2/HSP60 contributes to broad spectrum of hATSCs function via Oct4 regulation. Antioxid Redox Signal (2011) 0.80
RE: Heat shock proteins: their role in urological tumors. J Urol (2003) 0.79
Expression of heat shock proteins in premalignant and malignant urothelial lesions of bovine urinary bladder. Cell Stress Chaperones (2012) 0.78
Construction and selection of subtracted cDNA library of mouse hepatocarcinoma cell lines with different lymphatic metastasis potential. World J Gastroenterol (2004) 0.75
Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology (2008) 2.75
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Side-effects of treatments for locally advanced prostate cancer. BJU Int (2006) 2.03
Benign prostatic hyperplasia: counting the cost of its management. BJU Int (2010) 1.64
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol (2006) 1.63
Optimising repeat prostate biopsy decisions and procedures. BJU Int (2011) 1.62
Indicators for research performance evaluation: an overview. BJU Int (2012) 1.56
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int (2004) 1.53
Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am J Physiol Renal Physiol (2006) 1.44
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist (2013) 1.42
Radical prostatectomy vs watchful waiting. BJU Int (2005) 1.41
Can lifestyle modification lower the risk of prostate cancer? BJU Int (2010) 1.40
Fibrogenesis in Crohn's disease. Am J Gastroenterol (2006) 1.39
Are the National Institute for Health and Clinical Excellence guidelines that promulgate active surveillance for low-risk prostate cancer justified by the available evidence? BJU Int (2008) 1.39
Current prospects for the chemoprevention of prostate cancer. BJU Int (2010) 1.39
Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer (2003) 1.35
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol (2010) 1.34
TGF-beta1-induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation. Am J Physiol Renal Physiol (2005) 1.33
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer (2011) 1.32
The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol (2010) 1.28
Generation of an epigenetic signature by chronic hypoxia in prostate cells. Hum Mol Genet (2009) 1.21
Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology (2010) 1.20
Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int (2010) 1.16
Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) (2005) 1.16
Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate (2002) 1.15
Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate (2007) 1.10
Electronic learning can facilitate student performance in undergraduate surgical education: a prospective observational study. BMC Med Educ (2005) 1.09
Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol Cancer (2009) 1.08
Biomarker research in prostate cancer--towards utility, not futility. Nat Rev Urol (2011) 1.07
Epidemiology of testicular cancer. BJU Int (2009) 1.06
Spontaneous production of monocyte chemoattractant protein-1 and interleukin-8 by the human lumbar intervertebral disc. Spine (Phila Pa 1976) (2002) 1.04
The apoptosome pathway to caspase activation in primary human neutrophils exhibits dramatically reduced requirements for cytochrome C. J Exp Med (2003) 1.04
BMI and the risk of renal cell carcinoma. Curr Opin Urol (2011) 1.03
Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood (2003) 1.00
Targeting death receptors in bladder, prostate and renal cancer. J Urol (2006) 0.99
Gender differences in the renin-angiotensin and nitric oxide systems: relevance in the normal and diseased kidney. Kidney Blood Press Res (2007) 0.98
2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res (2009) 0.98
Exploring mechanisms involved in renal tubular sensing of mechanical stretch following ureteric obstruction. Am J Physiol Renal Physiol (2008) 0.98
The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer Biol Ther (2009) 0.97
Androgen-mediated resistance to apoptosis. Prostate (2002) 0.97
Delayed graft function: a dilemma in renal transplantation. BJU Int (2005) 0.97
Caffeic acid phenethyl ester-induced PC-3 cell apoptosis is caspase-dependent and mediated through the loss of inhibitors of apoptosis proteins. BJU Int (2004) 0.96
The Reten-World survey of the management of acute urinary retention: preliminary results. BJU Int (2008) 0.95
Mechanical deformation induced apoptosis in human proximal renal tubular epithelial cells is caspase dependent. J Urol (2004) 0.95
Biomarkers in renal cell carcinoma. Curr Opin Urol (2009) 0.95
Mechanical stretch regulates cell survival in human bladder smooth muscle cells in vitro. Am J Physiol Renal Physiol (2002) 0.93
Epstein criteria for insignificant prostate cancer. BJU Int (2011) 0.93
An antisense oligonucleotide to cIAP-1 sensitizes prostate cancer cells to fas and TNFalpha mediated apoptosis. Prostate (2004) 0.93
Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. J Proteome Res (2011) 0.91
Ensemble based system for whole-slide prostate cancer probability mapping using color texture features. Comput Med Imaging Graph (2011) 0.90
Chemotherapy for older patients with prostate cancer. BJU Int (2006) 0.90
Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int (2011) 0.90
The increasing incidence of mumps orchitis: a comprehensive review. BJU Int (2010) 0.89
Awareness of prostate cancer among the general public: findings of an independent international survey. Eur Urol (2003) 0.89
Apigenin drives the production of reactive oxygen species and initiates a mitochondrial mediated cell death pathway in prostate epithelial cells. Prostate (2005) 0.88
HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours. Eur Urol (2006) 0.87
Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int (2008) 0.87
Effects of heat shock and hypoxia on neonatal neutrophil lipopolysaccharide responses: altered apoptosis, Toll-like receptor-4 and CD11b expression compared with adults. Biol Neonate (2006) 0.87
The diagnosis and management of complex renal cysts. Curr Opin Urol (2010) 0.87
Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg (2005) 0.87
Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. Inflamm Bowel Dis (2008) 0.86
Glucose, but not glutamine, protects against spontaneous and anti-Fas antibody-induced apoptosis in human neutrophils. Clin Sci (Lond) (2002) 0.86
Increased E-cadherin expression in the ligated kidney following unilateral ureteric obstruction. Kidney Int (2008) 0.85
Polyunsaturated and monounsaturated fatty acids increase neutral lipid accumulation, caspase activation and apoptosis in a neutrophil-like, differentiated HL-60 cell line. Clin Sci (Lond) (2003) 0.85
The pathology of bladder cancer: An update on selected issues. BJU Int (2006) 0.84
Effects of titanocene dichloride derivatives on prostate cancer cells, specifically DNA damage-induced apoptosis. Prostate (2011) 0.84
Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer (2006) 0.84
The medical management of prostate cancer: a multidisciplinary team approach. BJU Int (2006) 0.84
Targeting apoptosis in prostate cancer: focus on caspases and inhibitors of apoptosis proteins. BJU Int (2005) 0.83
The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia. BJU Int (2004) 0.83